INTRODUCTION

The annual incidence of head and neck cancers is more than 650,000 cases worldwide with approximately 330,000 deaths per year.² Around 90% of all head and neck cancers are squamous cell carcinoma, known as head and neck squamous cell carcinoma (HNSCC).² HNSCC is the sixth most common cancer worldwide,¹ but the second most common cancer in Pakistan.⁴ HNSCC is associated with various lifestyle and environmental risk factors. HNSCC has been strongly associated with tobacco use, the risk for HNSCC in habitual
tobacco users is almost ten times higher than that in non-tobacco users. In fact, almost 70-80% of HNSCC diagnoses are associated with tobacco and alcohol use.5

Nearly 100 million people consume smokeless tobacco in Pakistan and India alone.6 Betel chewing, including betel quit and betel nut is common in South and Southeast Asia, and betel use also contributes to HNSCC cases.7 Habitual betel quit and betel nut use with or without added tobacco, has been classified as carcinogenic according to the International Agency for Research on Cancer (IARC).8 HNSCC in the developing countries vary from those in the Western world in terms of age at onset of the disease, site of disease, etiology, and genetic basis of the disease.

HNSCC cases without history of tobacco, alcohol and betel use were also observed during the sample collection of an ongoing molecular epidemiological study. This signifies the need to find out the possible risk factors for patients who never use tobacco, alcohol and betel in their lifetime, in order to prevent HNSCC.

METHODS

This study was approved by the Institutional Review Board (IRB) at the Karachi Institute of Biotechnology and Genetic Engineering (KIBGE), University of Karachi (KIBGE/ICE/003/2015 Nov. 25, 2015), and Jinnah Postgraduate Medical Centre Karachi.

Patients included in this study were from the oncology department of JPMC from January to December 2016. To define the demographics and potential risk factors for HNSCC in tobacco and/or betel nut addicted and non-addicted patients, a total of 211 HNSCC diagnosed patients were included in this study.

A written informed consent was obtained from all the patients. Detailed demographic and socioeconomic information including age, gender, income, and education; information about betel nut and chewing tobacco consumption, cigarette smoking, alcohol consumption and other addictions were collected from the patients or their attendants. Clinical data containing HNSCC site, HNSCC subsite, TNM stage, and grade, were obtained by reviewing the patients’ medical record files in the hospital with the permission of the head of the department.

Patients were considered addicted if they had used betel nut or any tobacco products at least once a day for one year or more during their lifetime. Patients were considered non-addicted if they had never used betel nut, any of the tobacco products, and alcohol in their lifetime. Tobacco products included Paan, Gutka, Naswar, Manpuri, Cigarette, and Hookah.

Chi-square statistical tests were performed to compare addicted and non-addicted patient groups. Student’s t-test (independent samples t test) was used to compare age between the two

Fig.1: Age and gender distributions of addicted and non-addicted patients.
groups and $p \leq 0.05$ was considered as the level of statistical significance. All the statistical analyses were performed by using SPSS Statistics 17.0, Microsoft Excel and Tools for Science (online).

**RESULTS**

In the current molecular epidemiological study database, 185 patients were identified as addicted while 26 were non-addicted. Ages of the patients were significantly different between the two groups. Non-addicted patients were significantly younger than addicted patients (Table-I). The non-addicted group had a higher proportion of patients being less than 40 years of age (42%), as compared to the addicted group (15%).

Females had a higher proportion in non-addicted patients group, while male patients were common in the addicted patients (Table-I and Fig.1). A significant difference was observed in income

**Table-I: Demographic data for addicted and non-addicted patients with HNSCC.**

| Parameter | Addicted (n = 185) | Non-addicted (n = 26) | $\chi^2$ value | p-value |
|-----------|-------------------|----------------------|----------------|---------|
| **Age**   |                   |                      |                |         |
| < 40 y    | 28 (15.1)         | 11 (42.3)            |                |         |
| 40-49 y   | 70 (37.8)         | 2 (7.7)              |                |         |
| 50-59 y   | 38 (20.5)         | 9 (34.6)             |                |         |
| 60-69 y   | 36 (19.5)         | 1 (3.8)              |                |         |
| > 69 y    | 13 (7.0)          | 3 (11.5)             |                |         |
| **Gender**|                   |                      | 19.0           | 0.001†  |
| Male      | 150 (81.1)        | 11 (42.3)            |                |         |
| Female    | 35 (18.9)         | 15 (57.7)            |                |         |
| **Income**| 14.4              | 0.006†               |                |         |
| < Rs.10,000 | 47 (31.5) | 2 (7.7) |                |         |
| Rs.10,000-Rs.19,000 | 87 (58.4) | 7 (34.6) |                |         |
| Rs.20,000-Rs.29,000 | 12 (8.1) | 1 (9.1) |                |         |
| Rs. 30,000-Rs.39,000 | 3 (2.0) | 0 (0.0) |                |         |
| > Rs. 40,000 | 0 (0.0) | 1 (9.1) |                |         |
| **Education**| 9.55          | 0.049†               |                |         |
| Uneducated | 116 (62.7) | 11 (42.3) |                |         |
| 8th grade or less | 39 (21.1) | 8 (30.7) |                |         |
| 9th - 10th grade | 19 (10.3) | 2 (7.7) |                |         |
| 11th - 12th grade | 7 (3.8) | 2 (7.7) |                |         |
| 13th - 14th grade | 4 (2.1) | 3 (11.5) |                |         |
| grade or high |                |                      |                |         |
| Mean age ± Std. | 49.80 ± 44.08 ± | 0.031† |                |         |
| Dev. y    | 12.04             | 15.81                |                |         |
| Median age, y | 48 | 47.50 |                |         |
| Age range, y | 25-90 | 18-70 |                |         |

**Table-II: HNSCC characteristics.**

| Parameter     | Addicted (n = 185) | Non-addicted (n = 26) | $\chi^2$ value | p-value |
|---------------|--------------------|-----------------------|----------------|---------|
| **HNSCC site**|                    |                       |                |         |
| Oral cavity   | 157 (84.9)         | 15 (57.7)             | 12.5           | 0.132   |
| Buccal mucosa | 103 (65.6)         | 5 (33.3)              |                |         |
| Tongue        | 30 (19.1)          | 5 (33.3)              |                |         |
| Lip           | 7 (4.4)            | 0 (0.0)               |                |         |
| Gingival      | 5 (3.2)            | 2 (13.3)              |                |         |
| Palate        | 4 (2.5)            | 1 (6.7)               |                |         |
| Alveolar ridge| 3 (1.9)            | 1 (6.7)               |                |         |
| Retromolar trigone | 2 (1.3) | 0 (0.0) |                |         |
| Floor of mouth| 1 (0.6)            | 0 (0.0)               |                |         |
| Buccal mucosa with any other subsite of oral cavity | 2 (1.3) | 1 (6.7) | | |
| Larynx        | 14 (7.6)           | 1 (3.8)               | 1.22           | 0.747   |
| Glottis       | 6 (42.9)           | 1 (100.0)             |                |         |
| Supraglottis  | 4 (28.6)           | 0 (0.0)               |                |         |
| Laryngeal wall| 3 (21.4)           | 0 (0.0)               |                |         |
| Vocal cords   | 1 (7.1)            | 0 (0.0)               |                |         |
| Hypopharynx   | 6 (3.2)            | 3 (11.5)              | 6.00           | 0.112   |
| Pyriform sinus| 4 (26.7)           | 0 (0.0)               |                |         |
| Hypopharyngeal wall | 1 (16.7) | 2 (66.7) | | |
| Cervical      | 1 (16.7)           | 0 (0.0)               |                |         |
| Post cricoid  | 0 (0.0)            | 1 (33.3)              |                |         |
| Oropharynx    | 2 (1.1)            | 0 (0.0)               |                |         |
| Tonsil        | 1 (50.0)           | 0 (0.0)               |                |         |
| Oropharyngeal wall | 1 (50.0) | 0 (0.0) | | |
| Nasal cavity  | 1 (1.5)            | 1 (3.8)               | 2.00           | 0.157   |
| Lateral wall  | 1 (100.0)          | 0 (0.0)               |                |         |
| Floor         | 0 (0.0)            | 1 (100.0)             |                |         |
| Eye           | 2 (1.1)            | 2 (7.7)               | 0.00           | 1.000   |
| Orbit         | 1 (50.0)           | 1 (50.0)              |                |         |
| Eyelid        | 1 (50.0)           | 1 (50.0)              |                |         |
| Ear           | 2 (1.1)            | 1 (3.8)               | 2.00           | 0.157   |
| Middle ear    | 2 (100.0)          | 0 (0.0)               |                |         |
| Auricle       | 0 (0.0)            | 1 (100.0)             |                |         |
| Nasopharynx   | 1 (0.5)            | 3 (11.5)              |                |         |
| Differentiation| 9.10              | 0.011                 |                |         |
| Well          | 52 (30.5)          | 1 (4.3)               |                |         |
| Moderate      | 111 (65.3)         | 19 (82.6)             |                |         |
| Poor          | 7 (4.1)            | 3 (13.0)              |                |         |
| Stage         | 5.21               | 0.391                 |                |         |

| Abbreviations: HNSCC: head and neck squamous cell carcinoma, Std. Dev.: standard deviation, *Chi-square analysis, †All female patients and 1 unemployed male patient were excluded, ‡Student’s t test with Satterthwaite’s adjustment for unequal variances. **Differentiation was not recorded for 15 addict and 3 non-addict patients, ††Stage was not recorded for 87 addict and 16 non-addict patients.
between the groups. In addicted group, higher numbers of patients (90%) were found in Rs. 20,000/month income groups. A significant difference was also observed in the education; non-addicted patients were more educated than addicted patients. The HNSCC site distribution differed significantly among the two groups; addicted patients were more likely to have oral cancers and a higher proportion of laryngeal, and oropharyngeal cancers, while non-addicted patients had a higher proportion of hypopharyngeal, nasal cavity, eye, ear, and nasopharyngeal cancers. Subsite distributions of all sites of HNSCC were not significantly different between the two groups (Table-II).

However, differences were observed in HNSCC site distributions between male and female patients; 97% females and 82% males of addicted group had oral cancers (Figs.2.A and 2.B), whereas in non-addicted patients, 53% of females and 64% of males had oral cancers (Figs.2.C and 2.D).

The majority of addicted patients showed with either well-differentiated or moderately differentiated HNSCC, while most non-addicted patients showed with moderately differentiated

Fig.2: Cancer site distributions between male and female patients of addicted and non-addicted patient’s groups.
OC, oral cavity; LX, larynx; HX, hypopharynx; OX, oropharynx; NC, nasal cavity; EE, eye; ER, ear; NX, nasopharynx.
HNSCC. Among addicted patients stage IV is commonly prevalent. Nevertheless, staging was not noted for a greater proportion of patients, so it is undecided whether staging was actually distributed differently between the groups.

**DISCUSSION**

The findings revealed that HNSCC in addicted and non-addicted patients varies in many ways. In particular, patient age, gender, income, education, and HNSCC site of occurrence differ between the two groups of patients. These outcomes are important because clinicians need to know that HNSCC is not only restricted to betel nut and tobacco product users, but that people who have never used betel and tobacco products are also becoming an increasing proportion of HNSCC patients. In the long run, understanding these differences may be beneficial in the prevention and management of such cancers.

Other similar studies have also found that non-addicted HNSCC patients tend to be younger than addicted HNSCC patients. Similar to other studies, this study have also reported that non-addicted HNSCC patients are more likely to be females. An association of non-addicted patients with elderly females has been reported, but in this study non-addicted patients are being associated with young females.

Data used in this study is collected from a government hospital, where most of the patients are from rural areas. In rural households, the breadwinners are usually males, and females are housewives. Among non-addicted patients, more than half are females, who are housewives and do not earn money, so they cannot be included in the income categories. To eliminate this bias, females are excluded from the income groups. Higher numbers of addicted patients earn < Rs. 20,000/month. It has been reported that nicotine in tobacco reduces the appetite, so people with low incomes might use tobacco products to suppress their appetites, ultimately leading to the development of HNSCC.

Similar to other studies, the oral cavity is the most common site of cancer development among all HNSCC patients, but some studies reported that larynx and hypopharynx, or oropharynx, are the most common sites of cancer. In addition, the oral cavity is also found to be the most common site of cancer occurrence in both addicted and non-addicted patient groups individually. It has also been found that HNSCC in either ever-smoker, or never-smoker patients are more likely to develop in oral cavity, but here addicted patients have greater proportion of oral cancers. In one study, the oropharynx is the most common site of HNSCC in never-smoker and never-drinker patients.

The results also revealed a huge gender based difference, almost all addicted females (except one female) having oral cancers. Furthermore, almost half of the non-addicted females had oral cancers and half had other sites of cancers. Both genders have higher proportions of oral cancers in addicted patients as compared to non-addicted patients, which might be due the direct contact of betel nut and tobacco products to the oral cavity, which can enhance carcinogenic effects in oral cavity. The high proportion of oral cancers as compared to other sites in non-addicted patients might be due to familial history, HPV infections, or poor oral hygiene.

Similar to other studies, most of the patients are presented with moderately differentiated cancers. Moreover, as 85% of addicted patients had oral cancers in this study, it is not surprising that when segregated by cancer site, in all three types of differentiation major proportions consist of oral cancers. Whereas in non-addicted patients, major proportion of only moderately differentiated cancers consist of oral cancers.

**CONCLUSIONS**

This case series has documented the clinical characteristics and demographics of addicted and non-addicted HNSCC patients. Non-addicted patients with HNSCC are commonly young females. Addicted patients commonly have oral cavity cancers which might be due to the habit of chewing tobacco or betel nut in addicted patients. This study suggests that no single known factor is responsible for HNSCC in non-addicted patients; however, occupational exposure, environmental tobacco smoke, and family history of cancer may contribute to HNSCC development in non-addicted patients, which needs further investigation with large sample size.

**Grant Support & Financial Disclosures:** None.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. doi: 10.3322/caac.21492
2. Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 2014;26:123-141. doi: 10.1016/j.coms.2014.01.001
3. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695-709. doi: 10.1016/S0140-6736(08)60728-X
4. Bilal S, Doss JG, Cella D, Rogers SN. Quality of life associated factors in head and neck cancer patients in a developing country using the FACT-H&N. J Craniofac Surg. 2015;43:274-280. doi: 10.1016/j.jcrs.2014.11.024
5. Jethwa AR, Khariwala SS. Tobacco-related carcinogenesis in head and neck cancer. Cancer Metastasis Rev. 2017;36:411-423. doi: 10.1007/s10555-017-9689-6
6. Zhou J, Michaud DS, Langevin SM, McClean MD, Eliot M, Kelsey KT. Smokeless tobacco and risk of head and neck cancer: Evidence from a case-control study in New England. Int J Cancer. 2013;132:1911-1917. doi: 10.1002/ijc.27839
7. Lee CH, Lee KW, Fang FM, Wu DC, Tsai SM, Chen PH, et al. The neoplastic impact of tobacco-free betel-quid on the histological type and the anatomical site of aerodigestive tract cancers. Int J Cancer. 2012;131:E733-E743. doi: 10.1002/ijc.27401
8. International Agency for Research on Cancer. Personal Habits and Indoor Combustions: A Review of Human Carcinogens. 2012;100E.
9. Dahlstrom KR, Little JA, Zafereo ME, Lung M, Wei Q, Sturgis EM. Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck. 2008;30:75-84.
10. Tan EH, Adelstein DJ, Droughton ML, Van Kirk MA, Lavertu P. Squamous cell head and neck cancer in nonsmokers. Am J Clin Oncol. 1997;20:146-150. doi: 10.1097/000005537-199910000-00002
11. Koch WM, Lango M, Sewell D, Zahurak M, Sidransky D. Head and Neck Cancer in Non-Smokers: A Distinct Clinical and Molecular Entity. Laryngoscope. 1999;109:1544-1551.
12. Bunney PE, Hansen M, LeSage M. Effects of isolated tobacco alkaloids and tobacco products on deprivation-induced food intake and meal patterns in rats. Pharmacol Biochem Behav. 2018;165:45-55. doi: 10.1016/j.pbb.2017.11.004
13. Hsu WL, Yu KJ, Chiang CJ, Chen TC, Wang CP. Head and Neck Cancer Incidence Trends in Taiwan, 1980–2014. Int J Head Neck Sci. 2017;1:180-189. doi: 10.6696/IJHNS.2017.0103.05
14. Misawa K, Mochizuki D, Endo S, Mima M, Misawa Y, Imai A, et al. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis. Mol Carcinog. 2017;56:1107-1116. doi: 10.1002/mc.22577
15. Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, Du Y, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013;8:e56823. doi: 10.1371/journal.pone.0056823
16. Wu YH, Yen CJ, Hsiao JR, Ou CY, Huang JS, Wong TY, et al. A comprehensive analysis on the association between tobacco-free Betel Quid and risk of Head and Neck Cancer in Taiwanese males. PLoS One. 2016;11:e0164937. doi: 10.1371/journal.pone.0164937
17. Akhtar A, Hussain I, Talha M, Shakeel M, Faisal M, Ameen M, et al. Prevalence and diagnostic of head and neck cancer in Pakistan. Pak J Pharm Sci. 2016;29:1839-1846.
18. Wyss AB, Hashibe M, Lee YC, Chuang SC, Muscat J, Chen C, et al. Smokeless tobacco use and the risk of head and neck cancer: pooled analysis of US studies in the INHANCE consortium. Am J Epidemiol. 2016;184:703-716. doi: 10.1093/aje/kwv075
19. Wiseman SM, Swede H, Stoler DL, Anderson GR, Riguall NR, Hicks WL, et al. Squamous cell carcinoma of the head and neck in nonsmokers and nondrinkers: an analysis of clinicopathologic characteristics and treatmest outcomes. Ann Surg Oncol. 2003;10:551-557. doi: 10.1245/ASO.2003.09.010
20. Hashim D, Sartori S, Brennan P, Curado MP, Wunsch-Filho V, Divaris K, et al. The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. Ann Oncol. 2016;27:1619-625. doi: 10.1093/annonc/mdw224

Authors’ Contribution:

MK: Concept and study design, analysis and interpretation of data, drafting the article, is responsible for integrity of research.
GH& UZ: Acquisition of data.
SS: Concept and study design, revising it critically for important intellectual content, final approval for publication.